Title: Clinical evaluation of dipeptide base peptidase 4(DPP-4)inhibitors and Metformin combination therapy intype 2 diabetes
Abstract: 【Objective】To observe the clinical efficacy and safety of therapy using dipeptide base peptidase 4(DPP-4) inhibitors of Saxagliptin and Metformin to type 2 diabetes. 【Methods】From February 2011 to February2013, 50 patients who had been diagnosed type 2 diabetes were assigned to control and treatment groups randomly and each group had 25 cases. Under the guide of recovery guidance of the diet and daily exercise, the control group was given Metformin alone, the treatment group was given Saxagliptin and Metformin, followed up for 12 weeks. The changes between the two groups of fasting blood glucose(FBS), 2 h postprandial blood glucose(2 h PG), glycated hemoglobin(HbA1c), HbA1 c compliance rate(with the standard value for HbA1 c 7%), fasting insulin(FINC), body mass index(BMI), and other biochemical markers, and recorded adverse drug reactions such as hypoglycemia,gastrointestinal discomfort were recorded and were contrasted. 【Results】After 12 weeks, the decreased HbA1 c values between treatment group and the control group were respectively(1.07 ± 0.66)%,(0.71±0.48)%, the HbA1 c levels decreased in the treatment group were significantly higher, the difference was significant statistically(t =2.2056, P 0.05). According the standard statistical Hb1 Ac 7%, the treatment group compliance rate(21/25) was significantly higher than the control group(14/25), the difference was also statistically significant(χ2=4.6667, P 0.05). Both groups' FBS, 2hPG compared with before treatment were significantly lower, but the decline in treatment group was lower than the control's, the difference was obvious(t =3.943, t =3.888, P 0.05). Two groups' fasting insulin levels was also up clearly than the before, and the treatment one was higher than the control one, it was difference statistically(t =2.071, P 0.05). The changes between two groups in the incidence of hypoglycemia,gastrointestinal adverse reactions, body mass indexes, liver and kidney functions, and blood lipid levels had no statistical differences(P 0.05).【Conclusions】It has significant effect to treat the type 2 diabetes with Saxagliptin and Metformin, and with less adverse reactions such as a low blood sugar.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot